|
|
|
24.06.25 - 14:33
|
Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire)
|
|
|
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 27, 2025, starting at 10:00 a.m. Pacific Time.
The live webcast can be accessed through the virtual shareholder meeting website at www.virtualshareholdermeeting.com/OMER2025. A general corporate overview and question-and-answer session will follow the business portion of the annual meeting.
As described in the Company's proxy statement, filed May 30, 2025, only shareholders of record as of the close of business on May 23, 2025 are entitled to vote at the Annual Meeting of Shareholders and any adjournment or postponement thereof. Shareholders of record will be able to attend the meeting, vote and submit questions via the virtual shareholder meeting website using the 16-digit control number provided in their proxy card or in the instructions accompanying their proxy materials.
Guests without a 16-digit contr...
|
|
|
|
|
|
|
15.05.25 - 22:06
|
Omeros Corporation Reports First Quarter 2025 Financial Results (Business Wire)
|
|
|
– Conference Call Today at 4:30 p.m. ET
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include:
Net loss for the first quarter of 2025 was $33.5 million, or $0.58 per share, compared to a net loss of $37.2 million, or $0.63 per share for the first quarter of 2024.
At March 31, 2025, we had $52.4 million of cash and short-term investments available for operations and debt servicing, a decrease of $37.7 million from December 31, 2024.
In March 2025, we resubmitted to the U.S. Food and Drug Administration (“FDA”) our Biologics License Application (“BLA”) seeking regulatory approval for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”). FDA accepted the resubmission for review as a class 2 resubmission and, pursuant to the Prescription Drug User Fee Act (“PDUFA”), assigned a target date for FDA action o...
|
|
|
|
|
12.05.25 - 23:09
|
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025 (Business Wire)
|
|
|
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Conference Call Details
For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events.
To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the “Call Me” option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a...
|
|
|
12.05.25 - 16:39
|
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 (Business Wire)
|
|
|
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company's 5.25% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026 Convertible Notes for newly issued 9.50% Convertible Senior Notes due 2029, with a conversion rate set at a 35% premium as described below (the “New Convertible Notes”). The exchange, which extends the maturity of a significant portion of the Company's outstanding indebtedness, is expected to close on or about May 14, 2025.
In addition, Omeros today announced that it has entered into an agreement (the “Note Conversion Agreement”) with an investor to convert $10 million aggregate principal amount of 2026 Convertible Notes into shares of the Company's common stock, par value $0.01 p...
|
|
|
|
|
12.05.25 - 14:42
|
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 (Business Wire)
|
|
|
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company's 5.25% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026 Convertible Notes for newly issued 9.50% Convertible Senior Notes due 2029, with a conversion rate set at a 35% premium as described below (the “New Convertible Notes”). The exchange, which extends the maturity of a significant portion of the Company's outstanding indebtedness, is expected to close on or about May 14, 2025.
In addition, Omeros today announced that it has entered into an agreement (the “Note Conversion Agreement”) with an investor to convert $10 million aggregate principal amount of 2026 Convertible Notes into shares of the Company's common stock, par value $0.01 p...
|
|
|
|
|
11.04.25 - 21:21
|
Omeros New Leukemia Drug Team Ignites Hope For Cancer Fight (Benzinga)
|
|
|
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.
Latest Ratings for OMER
DateFirmActionFromTo Oct 2021HC Wainwright & Co.MaintainsBuy Oct 2021JP MorganDowngradesNeutralUnderweight Oct 2021HC Wainwright & Co.MaintainsBuy
View More Analyst Ratings for OMER
View the Latest Analyst Ratings
read more...
|
|
|
10.04.25 - 15:15
|
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros′ Proprietary OncotoX-AML Clinical Program (Business Wire)
|
|
|
– The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers –
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high unmet need. Omeros' OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the cancer cells, thereby killing them.
Members of the Omeros Oncology Clinical Steering Committee include:
Naval Daver, M.D., Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (Chair of the Omeros Oncolog...
|
|
|
|
|
31.03.25 - 22:06
|
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results (Business Wire)
|
|
|
– Conference Call Today at 4:30 p.m. ET –
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, which include:
Net loss for the fourth quarter of 2024 was $31.4 million, or $0.54 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter of 2024.
For the year ended December 31, 2024, net loss was $156.8 million, or $2.70 per share, compared to a net loss of $117.8 million, or $1.88 per share in the prior year. The change in net loss reflects a $33.2 million decrease in the noncash gain from the remeasurement of the OMIDRIA contract royalty asset, a $6.6 million decrease in interest income earned and a $4.1 million gain on the early extinguishment of debt in December 2023, which were partially offset by a $6.2 million decrease in interest expense as a result of our debt repurchases and refinancing.
At December 31, 2024, we had $...
|
|
|
|
|
26.03.25 - 14:21
|
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 (Business Wire)
|
|
|
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Conference Call Details
For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events.
To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the “Call Me” option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register ...
|
|
|
13.03.25 - 14:03
|
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company′s OMS527 Program to Treat Cocaine Use Disorder (Business Wire)
|
|
|
– Successful Completion of Animal Drug Interaction Studies Triggers Funding for Phase 1b Clinical Trial in Patients with CUD –
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has received a funding commitment from the National Institute on Drug Abuse (NIDA) for the upcoming year (April 1, 2025 through March 31, 2026) in the amount of $4.02 million for clinical development of its lead orally administered phosphodiesterase 7 (PDE7) inhibitor OMS527 to treat cocaine use disorder (CUD), reducing or eliminating craving and relapse in patients with CUD. This grant will fund the Phase 1b clinical trial in patients with CUD to assess OMS527 safety and efficacy, with initial data readout expected in the fourth quarter of this year. NIDA's $4.02 million award was triggered by the successful outcome of drug-drug-interaction safety studies, also funded by NIDA and routinely required by the U.S. Food and Drug Administration (FDA), in which OMS527 was administered in conjunction...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
